Durable complete response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma

Kenta Takayasu, Koei Muguruma, Hidefumi Kinoshita

Article ID: 1387
Vol 6, Issue 1, 2022

VIEWS - 890 (Abstract) 352 (PDF)

Abstract


Immune checkpoint inhibitors, which promote or suppress the anti-tumor immune response, are becoming the mainstay of cancer treatment. In 2018, CheckMate 214 study showed a higher response rate with ipilimumab and nivolumab combination therapy compared to conventional therapy for advanced renal cell carcinoma. We report a case of complete response and durable response for two years to ipilimumab and nivolumab combination therapy in a patient with postoperative renal cancer recurrence that caused immune-related adverse events such as interstitial pneumonia and hepatotoxicity.


Keywords


Immune Checkpoint Inhibitor; Ipilimumab; Nivolumab; Combination Therapy; Advanced Renal Cell Carcinoma; Durable Response; Immune-related Adverse Events

Full Text:

PDF


References


1. Furukawa F. The Nobel Prize in Physiology or Medicine 2018 was awarded to cancer therapy by inhibition of negative immune regulation. Trends in Immunotherapy 2018; 2(1). doi: 10.24294/ti.v2.i3.1065

2. Seidel JA, OtsukaA, Kabashima K. Treating tumors with immune checkpoint inhibitors: Rationale and limitations. Trends in Immunotherapy 2017; 1(1): 2–9. doi: 10.24294/ti.v1.i1.20

3. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in sdvanced renal-cell carcinoma. New England Journal of Medicine 2018; 378(14): 1277–1290. doi: 10.1056/NEJMoa1712126

4. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020; 5(6): e001079. doi: 10.1136/esmoopen-2020-001079

5. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. Journal of Clinical Oncology 1999; 17(8): 2530–2540. doi: 10.1200/JCO.1999.17.8.2530

6. Iacovelli R, Alesini D, Palazzo A, et al. Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treatment Reviews 2014; 40(2): 271–275. doi: 10.1016/j.ctrv.2013.09.003

7. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine 2015; 373(19): 1803–1813. doi: 10.1056/NEJMoa1510665

8. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. The Journal of Immunology 2014; 192(12): 5451–5458. doi: 10.4049/jimmunol.1490019

9. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2019; 30(5): 706–720. doi: 10.1093/annonc/mdz056

10. Inaba H, Ariyasu H, Okuhira H, et al. Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. Trends in Immunotherapy 2020; 4(1): 18–26. doi: 10.24294/ti.v4.i1.606




DOI: https://doi.org/10.24294/ti.v6.i1.1387

Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Kenta Takayasu, Koei Muguruma, Hidefumi Kinoshita

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This site is licensed under a Creative Commons Attribution 4.0 International License.